401 related articles for article (PubMed ID: 31654653)
1. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice.
Yukitake H; Fujimoto T; Ishikawa T; Suzuki A; Shimizu Y; Rikimaru K; Ito M; Suzuki M; Kimura H
Pharmacol Biochem Behav; 2019 Dec; 187():172794. PubMed ID: 31654653
[TBL] [Abstract][Full Text] [Related]
2. TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy.
Ishikawa T; Hara H; Kawano A; Tohyama K; Kajita Y; Miyanohana Y; Koike T; Kimura H
J Pharmacol Exp Ther; 2023 Jun; 385(3):193-204. PubMed ID: 37001988
[TBL] [Abstract][Full Text] [Related]
3. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models.
Irukayama-Tomobe Y; Ogawa Y; Tominaga H; Ishikawa Y; Hosokawa N; Ambai S; Kawabe Y; Uchida S; Nakajima R; Saitoh T; Kanda T; Vogt K; Sakurai T; Nagase H; Yanagisawa M
Proc Natl Acad Sci U S A; 2017 May; 114(22):5731-5736. PubMed ID: 28507129
[TBL] [Abstract][Full Text] [Related]
4. OX2R-selective orexin agonism is sufficient to ameliorate cataplexy and sleep/wake fragmentation without inducing drug-seeking behavior in mouse model of narcolepsy.
Yamamoto H; Nagumo Y; Ishikawa Y; Irukayama-Tomobe Y; Namekawa Y; Nemoto T; Tanaka H; Takahashi G; Tokuda A; Saitoh T; Nagase H; Funato H; Yanagisawa M
PLoS One; 2022; 17(7):e0271901. PubMed ID: 35867683
[TBL] [Abstract][Full Text] [Related]
5. The orexin receptor 2 (OX2R)-selective agonist TAK-994 increases wakefulness without affecting cerebrospinal fluid orexin levels in cynomolgus monkeys.
Yamada R; Narita N; Ishikawa T; Kakehi M; Kimura H
Pharmacol Biochem Behav; 2024 Jan; 234():173690. PubMed ID: 38061670
[TBL] [Abstract][Full Text] [Related]
6. Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model.
Ishikawa T; Hara H; Kawano A; Kimura H
Pharmacol Biochem Behav; 2022 Oct; 220():173464. PubMed ID: 36108771
[TBL] [Abstract][Full Text] [Related]
7. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
Hoyer D; Jacobson LH
Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
[TBL] [Abstract][Full Text] [Related]
8. Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients.
Evans R; Kimura H; Alexander R; Davies CH; Faessel H; Hartman DS; Ishikawa T; Ratti E; Shimizu K; Suzuki M; Tanaka S; Yukitake H; Dauvilliers Y; Mignot E
Proc Natl Acad Sci U S A; 2022 Aug; 119(35):e2207531119. PubMed ID: 35994639
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism of the wake-promoting agent TAK-925.
Yin J; Kang Y; McGrath AP; Chapman K; Sjodt M; Kimura E; Okabe A; Koike T; Miyanohana Y; Shimizu Y; Rallabandi R; Lian P; Bai X; Flinspach M; De Brabander JK; Rosenbaum DM
Nat Commun; 2022 May; 13(1):2902. PubMed ID: 35614071
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists.
Zhang D; Perrey DA; Decker AM; Langston TL; Mavanji V; Harris DL; Kotz CM; Zhang Y
J Med Chem; 2021 Jun; 64(12):8806-8825. PubMed ID: 34101446
[TBL] [Abstract][Full Text] [Related]
11. Orexin receptor 2 expression in the posterior hypothalamus rescues sleepiness in narcoleptic mice.
Mochizuki T; Arrigoni E; Marcus JN; Clark EL; Yamamoto M; Honer M; Borroni E; Lowell BB; Elmquist JK; Scammell TE
Proc Natl Acad Sci U S A; 2011 Mar; 108(11):4471-6. PubMed ID: 21368172
[TBL] [Abstract][Full Text] [Related]
12. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes.
Willie JT; Chemelli RM; Sinton CM; Tokita S; Williams SC; Kisanuki YY; Marcus JN; Lee C; Elmquist JK; Kohlmeier KA; Leonard CS; Richardson JA; Hammer RE; Yanagisawa M
Neuron; 2003 Jun; 38(5):715-30. PubMed ID: 12797957
[TBL] [Abstract][Full Text] [Related]
13. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat.
Dugovic C; Shelton JE; Aluisio LE; Fraser IC; Jiang X; Sutton SW; Bonaventure P; Yun S; Li X; Lord B; Dvorak CA; Carruthers NI; Lovenberg TW
J Pharmacol Exp Ther; 2009 Jul; 330(1):142-51. PubMed ID: 19363060
[TBL] [Abstract][Full Text] [Related]
14. Arousal effect of orexin A depends on activation of the histaminergic system.
Huang ZL; Qu WM; Li WD; Mochizuki T; Eguchi N; Watanabe T; Urade Y; Hayaishi O
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9965-70. PubMed ID: 11493714
[TBL] [Abstract][Full Text] [Related]
15. Design and Synthesis of Orexin 1 Receptor-Selective Agonists.
Iio K; Hashimoto K; Nagumo Y; Amezawa M; Hasegawa T; Yamamoto N; Kutsumura N; Takeuchi K; Ishikawa Y; Yamamoto H; Tokuda A; Sato T; Uchida Y; Inoue A; Tanimura R; Yanagisawa M; Nagase H; Saitoh T
J Med Chem; 2023 Apr; 66(8):5453-5464. PubMed ID: 37043436
[TBL] [Abstract][Full Text] [Related]
16. Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists.
Nagahara T; Saitoh T; Kutsumura N; Irukayama-Tomobe Y; Ogawa Y; Kuroda D; Gouda H; Kumagai H; Fujii H; Yanagisawa M; Nagase H
J Med Chem; 2015 Oct; 58(20):7931-7. PubMed ID: 26267383
[TBL] [Abstract][Full Text] [Related]
17. Discovery of TAK-925 as a Potent, Selective, and Brain-Penetrant Orexin 2 Receptor Agonist.
Fujimoto T; Rikimaru K; Fukuda K; Sugimoto H; Masuda K; Ohyabu N; Banno Y; Tokunaga N; Kawamoto T; Tomata Y; Kumagai Y; Iida M; Nagano Y; Yoneyama-Hirozane M; Shimizu Y; Sasa K; Ishikawa T; Yukitake H; Ito M; Aoyama K; Matsumoto T
ACS Med Chem Lett; 2022 Mar; 13(3):457-462. PubMed ID: 35295087
[TBL] [Abstract][Full Text] [Related]
18. The present and future of synthetic orexin receptor agonists.
Saitoh T; Sakurai T
Peptides; 2023 Sep; 167():171051. PubMed ID: 37422012
[TBL] [Abstract][Full Text] [Related]
19. Increase of histaminergic tuberomammillary neurons in narcolepsy.
Valko PO; Gavrilov YV; Yamamoto M; Reddy H; Haybaeck J; Mignot E; Baumann CR; Scammell TE
Ann Neurol; 2013 Dec; 74(6):794-804. PubMed ID: 24006291
[TBL] [Abstract][Full Text] [Related]
20. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.
Sun Y; Tisdale RK; Kilduff TS
Front Neurol Neurosci; 2021; 45():22-37. PubMed ID: 34052813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
